Recently, there has been a renewed interest in therapeutically exploiting type I interferons such as IFNα, which is the first bio-therapeutic approved and that plays a documented role as anticancer agent in solid cancers as well as in hematological malignancies [6]. Here, IFNA1 is linked to hematologic disorder.